DUSP23 Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population, offering a loss-of-function model for the dual-specificity phosphatase DUSP23 in a human non-small cell lung cancer background. This polyclonal knockout pool, generated via CRISPR/Cas9-mediated gene disruption, provides a heterogeneous mixture of edited alleles, enabling the study of DUSP23-dependent signaling dynamics without clonal selection. Designed for advanced biomedical research, this product facilitates the dissection of MAPK signaling feedback mechanisms in EGFR-mutant lung adenocarcinoma.
The parental NCI-H1975 cell line is a well-characterized human lung adenocarcinoma epithelial model derived from a female patient, harboring activating EGFR L858R and T790M mutations (ATCC CRL-5908). These mutations confer constitutive EGFR signaling and sensitivity to tyrosine kinase inhibitors (TKIs), making NCI-H1975 a critical system for studying TKI resistance and EGFR-dependent oncogenic pathways. The cells maintain an epithelial morphology and are widely employed in non-small cell lung cancer research, particularly for evaluating MAPK pathway activation and therapeutic responses.
DUSP23 functions as a dual-specificity phosphatase that dephosphorylates and inactivates the MAP kinases ERK1/2 and JNK1/2/3, acting as a critical negative regulator of the EGFR-MAPK signaling axis. Upon EGFR activation, the RAS-RAF-MEK-ERK cascade is triggered via adaptor proteins GRB2 and SOS, leading to ERK1/2 phosphorylation; DUSP23 targets activated ERK1/2 to attenuate signal transduction. Additionally, DUSP23 modulates JNK activity, often induced by oxidative stress, to control stress-responsive pathways. By dephosphorylating both ERK and JNK, DUSP23 serves as a convergence point for feedback inhibition, shaping the duration and intensity of MAPK pathway output. Consequently, DUSP23 knockout removes this negative constraint, potentially enhancing and prolonging ERK1/2 and JNK phosphorylation upon EGFR stimulation.
In the NCI-H1975 background, disruption of DUSP23 is particularly relevant due to the cell line’s dependence on oncogenic EGFR signaling. The EGFR L858R/T790M double mutant drives persistent activation of downstream MAPK pathways, and negative feedback mechanisms involving dual-specificity phosphatases like DUSP23 may influence therapeutic sensitivity to EGFR inhibitors. Loss of DUSP23 function could alter the phosphorylation dynamics of ERK1/2 and JNK, thereby modulating proliferative and survival signals. This knockout model enables the investigation of how DUSP23 contributes to adaptive responses in EGFR-mutant lung cancer, including potential roles in acquired resistance to first- and third-generation TKIs. Moreover, it provides a platform to dissect the interplay between oxidative stress, DUSP23-mediated dephosphorylation, and MAPK pathway rewiring.
This polyclonal DUSP23 knockout pool is suitable for a range of functional studies, including western blot analysis of phospho-ERK and phospho-JNK to assess pathway activation, MAPK pathway reporter assays to quantify signal transduction, and cell proliferation assays to evaluate growth phenotypes. It can be employed in drug sensitivity screens with EGFR inhibitors such as gefitinib or osimertinib to probe resistance mechanisms, and in functional genomics approaches to identify novel regulators of MAPK signaling. Researchers may use this model to explore feedback regulation of EGFR-MAPK cascades, investigate the impact of DUSP23 loss on tumor cell fitness, and compare signaling dynamics between wild-type and knockout populations. For further information or custom inquiries, please contact Ascent Research.
